Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P08311

UPID:
CATG_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P08311; Q6IBJ6; Q9UCA5; Q9UCU6

BACKGROUND:
Cathepsin G is a multifunctional serine protease that not only cleaves a wide range of substrates with high specificity but also possesses antibacterial properties. It plays a crucial role in the activation and recruitment of platelets, B cells, T cells, and natural killer cells, enhancing their cytotoxicity. Additionally, it is involved in the cleavage of several important molecules like complement C3, thrombin receptor F2R, and coagulation factors, underlining its significance in immune response and hemostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Cathepsin G offers a promising avenue for therapeutic intervention. Its critical role in immune response regulation and hemostasis positions it as a potential target for the development of novel therapies aimed at treating a broad spectrum of diseases, including immune dysfunctions and coagulation disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.